美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Emera Inc.

45.50

-0.2000-0.44%

盤後：45.500.00000.00%16:39 EDT

成交量：10.13萬

成交額：461.14萬

市值：135.54億

市盈率：21.99

高：45.81

開：45.81

低：45.35

收：45.70

資料載入中...

總覽公司新聞公告

回調信號增強，歐元還能否站穩多頭陣營？

澳元/美元周度展望：美國CPI與澳大利亞就業數據備受關注

諾和諾德宣佈7.2mg司美格魯肽的上市申請獲得歐洲藥品管理局(EMA)受理用於體重管理。此次上市申請是基於III期STE

諾和諾德(NVO.US)7.2mg司美格魯肽上市申請獲EMA受理

【諾和諾德(NVO.US)7.2mg司美格魯肽上市申請獲EMA受理】智通財經APP獲悉，7月8日，諾和諾德(NVO.US

Pi幣強勢迴歸？Pi網絡藉助Zypto整合衝擊DeFi　能否迎來全面反彈？

技術分析：美元表現不佳，美元/加元面臨拋售壓力

【葛蘭素史克(GSK.US)口服靶向新藥“利奈昔巴特片”在中國擬納入優先審評】智通財經APP獲悉，7月4日，中國國家藥監

藥明合聯新加坡基地達成機械完工里程碑，加速生物偶聯藥全球化佈局

Bitget鏈上交易（Onchain）產品更新，全面優化止盈止損模塊

XRP 價格預測：重大“突破”預計 90 天內發生　XRP 有望飆至 $589？

突破通用領域推理的瓶頸！清華NLP實驗室強化學習新研究RLPR

樂普生物：EGFR ADC聯合PD-1單抗IND申請獲EMA批准

生物药大时代

港股異動 | 海普瑞(09989)午前漲超3% 近日收到EMA簽發關於依諾肝素鈉注射液新增生產商的批准通知

【港股異動 | 海普瑞(09989.HK)午前漲超3% 近日收到EMA簽發關於依諾肝素鈉注射液新增生產商的批准通知】智通

【灣區早參】深圳二手房在售量超過72000套；廣州發佈智能網聯汽車發展計劃

首個三期臨牀99.9%有效艾滋預防藥在美獲批，吉利德：期待儘快帶到中國

XRP牛市起點？監管勝利是否足以引爆300%漲幅？

百奧泰：烏司奴單抗注射液獲歐洲藥品管理局人用藥品委員會積極意見

一年兩針！吉利德突破性長效HIV療法獲FDA批准上市

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/EMA/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":45.5,"timestamp":1752609600000,"preClose":45.7,"halted":0,"volume":101254,"hourTrading":{"tag":"盘后","latestPrice":45.5,"preClose":45.5,"latestTime":"16:39 EDT","volume":47686,"amount":2173556.02918,"timestamp":1752611948445},"delay":0,"floatShares":297632664,"shares":297900000,"eps":2.069006,"marketStatus":"未開盤","change":-0.2,"latestTime":"07-15 16:00:00 EDT","open":45.81,"high":45.81,"low":45.35,"amount":4611395.7339,"amplitude":0.010066,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.069006,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1752652800000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":45.7,"dividendRate":0.04658,"postHourTrading":{"tag":"盘后","latestPrice":45.5,"preClose":45.5,"latestTime":"16:39 EDT","volume":47686,"amount":2173556.02918,"timestamp":1752611948445},"volumeRatio":1.247603,"impliedVol":0,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":297632664,"roa":"2.73%","roe":"7.21%","lyrEps":1.186627,"volumeRatio":1.247603,"shares":297900000,"dividePrice":2.102888,"high":45.81,"amplitude":0.010066,"preClose":45.7,"low":45.35,"week52Low":43.9012,"pbRate":"1.51","psRate":"2.37","week52High":46.45,"institutionHeld":0,"latestPrice":45.5,"eps":2.069006,"divideRate":0.046217,"volume":101254,"delay":0,"ttmEps":2.069006,"open":45.81,"prevYearClose":45.28,"prevWeekClose":46.07,"prevMonthClose":45.82,"prevQuarterClose":45.82,"fiveDayClose":45.44,"twentyDayClose":45.13,"earningDate":1754582400000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551984198","title":"回調信號增強，歐元還能否站穩多頭陣營？","url":"https://stock-news.laohu8.com/highlight/detail?id=2551984198","media":"英为财情","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551984198?lang=zh_tw&edition=fundamental","pubTime":"2025-07-15 22:01","pubTimestamp":1752588060,"startTime":"0","endTime":"0","summary":"分析认为，欧元的阶段性强势更多是受到美元内部调整及仓位平衡的驱动，而非欧洲经济自身的基本面改善；当前欧元仍为G10货币中持仓最集中的一员，短期内或面临阶段性获利回吐压力。整体来看分析认为，基本面对欧元并不构成持续性支撑，未来的表现仍更多取决于美元走势及欧洲经济后续数据。恐惧与贪婪指数以及整体市场情绪指标显示，市场对欧元后市的看涨共识有所降温，短期投机性资金偏好降低。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cn.investing.com/news/forex-news/article-2886647","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investing_news","symbols":["EMA","BK4081"],"gpt_icon":0},{"id":"2551900022","title":"澳元/美元周度展望：美國CPI與澳大利亞就業數據備受關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2551900022","media":"英为财情","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551900022?lang=zh_tw&edition=fundamental","pubTime":"2025-07-14 18:00","pubTimestamp":1752487200,"startTime":"0","endTime":"0","summary":"美国CPI与美联储政策：美元走势的潜在催化剂本周二的美国6月CPI数据备受关注，尤其是美联储主席杰罗姆·鲍威尔近期提及特朗普关税政策可能在夏季推高通胀压力。然而，若美国数据或澳大利亚就业数据引发看跌情绪，0.65支撑位可能面临考验。交易员需密切关注周二的美国CPI、周四的澳大利亚就业报告，以及7月30日的季度CPI数据，这些将是决定未来走势的关键催化剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cn.investing.com/news/forex-news/article-2883902","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investing_news","symbols":["EMA","BK4150","BK4585","BK4139","CNY","BK4081","BK4588","BK4570","RNA","PPI","RSI","BK4505"],"gpt_icon":0},{"id":"2550029687","title":"諾和諾德宣佈7.2mg司美格魯肽的上市申請獲得歐洲藥品管理局(EMA)受理用於體重管理。此次上市申請是基於III期STE","url":"https://stock-news.laohu8.com/highlight/detail?id=2550029687","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550029687?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 17:15","pubTimestamp":1752052556,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"78fedc083232cad66c4305af131d712b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["EMA","BK4599","BK4007","III","BK4135","BK4134","LU1093756168.USD","IE00BKVL7J92.USD","BK4008","STEP","BK4532","LU1093756325.SGD","IE00BZ1G4Q59.USD","NVO","BK4588","BK4585","UP","LU0154236417.USD","BK4081"],"gpt_icon":0},{"id":"2550681411","title":"諾和諾德(NVO.US)7.2mg司美格魯肽上市申請獲EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2550681411","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550681411?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 16:21","pubTimestamp":1752049283,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月8日，诺和诺德(NVO.US)宣布7.2mg司美格鲁肽的上市申请获得欧洲药品管理局(EMA)受理，用于体重管理。此次上市申请是基于III期STEP UP研究和III期STEP UP T2D研究的积极结果。结果显示，患者平均基线体重为113kg，治疗第72周，7.2mg司美格鲁肽组、2.4mg司美格鲁肽组和安慰剂组患者的体重分别减轻了20.7%、17.5%和2.4%。此外，7.2mg司美格鲁肽组有33.2%的患者实现了体重减轻25%以上的效果，而2.4mg司美格鲁肽组和安慰剂组的这一比例分别为16.7%和0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"78fedc083232cad66c4305af131d712b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BKVL7J92.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4532","BK4081","BK4588","NVO","BK4599","BK4007","EMA","LU1093756168.USD","LU0154236417.USD","BK4585"],"gpt_icon":0},{"id":"2550681251","title":"【諾和諾德(NVO.US)7.2mg司美格魯肽上市申請獲EMA受理】智通財經APP獲悉，7月8日，諾和諾德(NVO.US","url":"https://stock-news.laohu8.com/highlight/detail?id=2550681251","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550681251?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 16:21","pubTimestamp":1752049283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"78fedc083232cad66c4305af131d712b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4134","BK4008","III","LU1093756168.USD","BK4585","IE00BZ1G4Q59.USD","BK4599","UP","BK4081","NVO","LU1093756325.SGD","BK4135","EMA","IE00BKVL7J92.USD","BK4532","STEP","BK4588","LU0154236417.USD","BK4007"],"gpt_icon":0},{"id":"2549349705","title":"Pi幣強勢迴歸？Pi網絡藉助Zypto整合衝擊DeFi　能否迎來全面反彈？","url":"https://stock-news.laohu8.com/highlight/detail?id=2549349705","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549349705?lang=zh_tw&edition=fundamental","pubTime":"2025-07-05 13:00","pubTimestamp":1751691600,"startTime":"0","endTime":"0","summary":"\n                                        \n去中心化支付应用 Zypto 已在其移动平台上线 Pi币（PI） 支持，意味着“先锋者”（Pioneers）现在可以通过其实体与虚拟 VISA卡，将持有的资产用于日常消费支付。\n\n\n\n随着这一新场景的落地，Pi币的价格预测展现出强烈看涨信号。截至撰写时，Zypto 支付应用已覆盖 10 多个国家，支持超过 24,000 种加密资产交易与支付，为 Pi 币打开了更广泛的实用性与主流采纳空间。\n\n\n\n\n\n\n\n此外，Zypto 还推出了一款基于 Pi 的去中心化应用（dApp），具备跨链互操作能力，用户可通过该应用将 Pi 代币兑换为其他加密资产，进一步拓展了 Pi 的资产流动性与 DeFi 融合度。\n\n\n\n这一消息发布的时间点正值 “Pi 日”活动后不久。该活动由开发团队举办，旨在向社区介绍若干新功能与生态进展。\n\n\n\n尽管 Pi 公链主网已于 2 月上线，但其生态建设进展缓慢，一度引发市场质疑。而本次与 Zypto 的深度集成，被视为激活生态发展的关键一步，有望在 Pi...                                    ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cryptonews.com/cn/news/pi-coin-price-prediction-pi-network-gains-defi-momentum-with-zypto-integration-is-a-full-recovery-on-the-table/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cryptonews_cn_highlight","symbols":["BK4594","03439","BK4585","09042","BK4141","BTC.USD.CC","03042","PI","BK1611","MBTmain","XBTmain","03008","BTCmain","BK4601","EMA","BTC.USD.HKCC","83042","BK4588","09008","BK4081","09439","LU1878469433.USD"],"gpt_icon":1},{"id":"2548239816","title":"技術分析：美元表現不佳，美元/加元面臨拋售壓力","url":"https://stock-news.laohu8.com/highlight/detail?id=2548239816","media":"英为财情","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548239816?lang=zh_tw&edition=fundamental","pubTime":"2025-07-04 18:21","pubTimestamp":1751624460,"startTime":"0","endTime":"0","summary":"虽然短时内美元/加元有所反弹，美元/加元仍面临抛售压力，美元回吐了昨日非农数据公布后的大部分涨幅。特朗普的巨额法案在共和党控制的众议院通过，预计这将使财政债务增加超过3万亿美元。由于7月9日关税截止日期的不确定性，加元的表现逊于其他同行。技术分析技术指标明确指向下方，预示着可能跌破6月低点1.3539，延续下行趋势。总之，美元/加元目前的看跌阶段似乎还有更多下行空间，可能在1.3460附近形成新的低点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cn.investing.com/news/forex-news/article-2873023","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investing_news","symbols":["EMA","BK4081"],"gpt_icon":0},{"id":"2548330995","title":"【葛蘭素史克(GSK.US)口服靶向新藥“利奈昔巴特片”在中國擬納入優先審評】智通財經APP獲悉，7月4日，中國國家藥監","url":"https://stock-news.laohu8.com/highlight/detail?id=2548330995","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548330995?lang=zh_tw&edition=fundamental","pubTime":"2025-07-04 10:44","pubTimestamp":1751597061,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1645745479.HKD","BK4017","CDE.AU","LU0306806265.USD","LU0225284248.USD","IBAT","LU1400636491.USD","LU0545562505.USD","BK4007","LU1829250122.USD","LU0058720904.USD","CDE","LU1400636657.SGD","GSK","BK7050","LU1228905037.USD","BK4588","LU0289739699.SGD","LU0575583348.USD","LU0211331839.USD","LU1098665638.USD","BK4585","LU1223082196.USD","LU1223083913.SGD","LU0971552830.HKD","LU1228905540.USD","LU1302929846.USD","LU1487256676.USD","EMA","LU1670756490.USD","IE0034235071.USD","LU0985481810.HKD","LU1046248800.SGD","LU1035777561.USD","LU1015430645.USD","IE00BWDBJ516.SGD","LU0321505868.SGD","LU1400636574.HKD","LU0971552673.USD","GSK.UK","LU0225771236.USD","LU0321505439.SGD","LU1223082519.USD","LU1481600234.SGD","LU0203345920.USD","BK5011","PBC","LU1202635105.USD","LU1064927863.SGD","LU1481599808.USD"],"gpt_icon":0},{"id":"2548465885","title":"藥明合聯新加坡基地達成機械完工里程碑，加速生物偶聯藥全球化佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2548465885","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548465885?lang=zh_tw&edition=fundamental","pubTime":"2025-07-01 17:34","pubTimestamp":1751362440,"startTime":"0","endTime":"0","summary":"中国上海和新加坡 2025年7月1日 /美通社/ -- 6月30日，全球领先的生物偶联药物合同研究、开发和生产企业药明合联欣然宣布，其位于新加坡大士生物医药园的生产基地正式完成机械完工，这一里程碑事件标志着这座总建筑面积约25,000平方米的生产基地将全面进入设备及设施调试和验证阶段。作为药明合联全球化战略的重要部署，新加坡基地建设秉承公司无锡基地的\"完美执行\"理念和\"药明速度\"，皆在为客户打造敏捷、灵活的一站式解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4722094_ZH22094_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4081","SG9999014674.SGD","BK4231","ADC","BK4080","LU2488822045.USD","EMA","02268","BK1141"],"gpt_icon":0},{"id":"2547006394","title":"Bitget鏈上交易（Onchain）產品更新，全面優化止盈止損模塊","url":"https://stock-news.laohu8.com/highlight/detail?id=2547006394","media":"Odaily","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547006394?lang=zh_tw&edition=fundamental","pubTime":"2025-06-30 16:19","pubTimestamp":1751271580,"startTime":"0","endTime":"0","summary":"Odaily星球日报讯 据官方消息，Bitget 对其链上交易（Onchain）产品进行多项优化，以全面提升用户交易体验，更新 Bitget App 至最新版本即可体验。本次升级主要包括：\n止盈止损功能升级：可一键预设止盈/止损，助力掌握交易节奏\n交易指标功能更新：新增 EMA、RSI 等多项专业数据，精准分析行情\n当前委托订单功能优化：支持查看滑点、金额等详情，全面掌握交易信息\n新手专属教程上线：可轻松查看操作教程，便于快速上手交易\nPIN 码功能全新上线：下单时多重防护，守护资金安全\n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.odaily.news/newsflash/436855?source=share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"odaily_live","symbols":["BK4081","RSI","BK4150","EMA"],"gpt_icon":0},{"id":"2546953617","title":"XRP 價格預測：重大“突破”預計 90 天內發生　XRP 有望飆至 $589？","url":"https://stock-news.laohu8.com/highlight/detail?id=2546953617","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546953617?lang=zh_tw&edition=fundamental","pubTime":"2025-06-27 13:00","pubTimestamp":1751000400,"startTime":"0","endTime":"0","summary":"\n在周末跌破 $1.90 后，XRP（XRP）正悄悄重新获得市场关注，随着地缘政治新闻改变市场情绪，其价格开始回升。\nXRP 曾短暂跌破心理关口 $2，但在美国前总统川普介入调停伊朗与以色列之间的停火后，买盘迅速回流，带动价格反弹。 ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cryptonews.com/cn/news/xrp-price-prediction-major-breakout-predicted-within-90-days-589-xrp-possible/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cryptonews_cn_highlight","symbols":["BK4081","BK1611","BK4585","83042","BK4588","MBTmain","09439","BTC.USD.HKCC","03008","03042","BK4601","EMA","09008","09042","BK4594","BTC.USD.CC","03439"],"gpt_icon":1},{"id":"2546642507","title":"突破通用領域推理的瓶頸！清華NLP實驗室強化學習新研究RLPR","url":"https://stock-news.laohu8.com/highlight/detail?id=2546642507","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546642507?lang=zh_tw&edition=fundamental","pubTime":"2025-06-27 10:30","pubTimestamp":1750991400,"startTime":"0","endTime":"0","summary":"针对这一关键挑战，清华大学自然语言处理实验室提出了一项关键性技术 —— 基于参考概率奖励的强化学习。同时，RLPR 提出基于奖励标准差的动态过滤机制，进一步提升强化学习的稳定性和性能提升。目前 RLPR 相关代码、模型、数据、论文均已开源。结果表明，PR 在 0.5B 规模即取得了显著优于规则奖励和验证器模型奖励的质量。RLPR 在 Gemma、Llama、Qwen 等不同基座模型上均稳定提升推理能力总结RLPR 提出了创新的 Prob-to-Reward 奖励机制，解决了现有 RLVR 范式的领域依赖问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-06-27/doc-infcnrzr2751855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","RL","BK4588","BK4081","LU0006061336.USD","BK4585","BK4202"],"gpt_icon":0},{"id":"2546275727","title":"樂普生物：EGFR ADC聯合PD-1單抗IND申請獲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2546275727","media":"生物药大时代","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546275727?lang=zh_tw&edition=fundamental","pubTime":"2025-06-26 09:45","pubTimestamp":1750902347,"startTime":"0","endTime":"0","summary":"2025年6月24日，乐普生物科技股份有限公司的MRG003联合普特利单抗对比MRG003单药治疗局部晚期头颈鳞癌的II期研究的临床试验申请获得欧洲药品管理局批准，计划将于2025Q3启动入组。该研究是全球首个EGFR ADC联合PD-1单抗在局晚期头颈鳞癌的临床研究。EGFR ADC与普特利单抗联合治疗在EGFR阳性实体瘤患者中具有良好的耐受性和令人鼓舞的抗肿瘤活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626094830a71df665&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626094830a71df665&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02157","BK1161","EMA"],"gpt_icon":0},{"id":"2545847686","title":"港股異動 | 海普瑞(09989)午前漲超3% 近日收到EMA簽發關於依諾肝素鈉注射液新增生產商的批准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2545847686","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545847686?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 11:42","pubTimestamp":1750736554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海普瑞午前涨超3%，截至发稿，涨3.09%，报5.33港元，成交额872.01万港元。消息面上，海普瑞发布公告，公司近日收到欧洲药品管理局签发的关于依诺肝素钠注射液新增生产商的批准通知。据介绍，海普瑞坪山园区新建预灌封制剂生产线项目于2022年正式启动，首期新建三条预灌封生产线设计产能为3.3亿支╱年，其按照中国、欧美药品法规标准设计建造，用于生产依诺肝素钠预灌封注射液。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","BK1191","002399","EMA","09989","BK4081","BK0070"],"gpt_icon":0},{"id":"2545476550","title":"【港股異動 | 海普瑞(09989.HK)午前漲超3% 近日收到EMA簽發關於依諾肝素鈉注射液新增生產商的批准通知】智通","url":"https://stock-news.laohu8.com/highlight/detail?id=2545476550","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545476550?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 11:42","pubTimestamp":1750736554,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09989","BK0239","002399","BK0188","BK4081","EMA","BK0070","BK1191"],"gpt_icon":0},{"id":"2545299104","title":"【灣區早參】深圳二手房在售量超過72000套；廣州發佈智能網聯汽車發展計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=2545299104","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545299104?lang=zh_tw&edition=fundamental","pubTime":"2025-06-24 08:28","pubTimestamp":1750724898,"startTime":"0","endTime":"0","summary":"主要原因为：集团铝合金产品及氧化铝产品销售价格均较2024年同期上涨，销售数量亦有所增加。mCRPC为晚期前列腺癌的一种，属对去势治疗产生耐药并可能出现新转移的病症。此次于美的威灵量产的产品为该集团Gen3.0高压700V半桥氮化镓芯片产品。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1960965","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0287142896.SGD","BK1500","SG9999001093.SGD","BK1237","LU1166156734.SGD","LU0702159699.USD","EMA","BK1592","02338","LU0737861699.HKD","02577","LU1224709979.USD","01378","BK1171","LU0173614495.USD","BK1522","SG9999014674.SGD","02617","BK1175","CCA","BK4081","02533","BK1163","SG9999006597.SGD","01497","BK4023","BK1594","LU1808992512.USD","IE0034224299.USD"],"gpt_icon":1},{"id":"2545250490","title":"首個三期臨牀99.9%有效艾滋預防藥在美獲批，吉利德：期待儘快帶到中國","url":"https://stock-news.laohu8.com/highlight/detail?id=2545250490","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545250490?lang=zh_tw&edition=fundamental","pubTime":"2025-06-23 17:58","pubTimestamp":1750672684,"startTime":"0","endTime":"0","summary":"研究数据显示，在3期临床研究PURPOSE 1 和 PURPOSE 2 中，超过99.9%接受 Yeztugo的受试者保持HIV 检测阴性。吉利德中国向蓝鲸新闻表示，来那帕韦用于HIV预防已在美国获批，目前，在其他国家或地区都尚未获批。我们正在和政府、卫生部门及监管机构密切沟通，期待尽快将这一革新的HIV预防方案带到中国，帮助加速国内的HIV防控进程。“Yeztugo一年仅需给药两次，在临床研究中展现出了卓越效果，这意味着它有可能革新HIV 的预防格局。”抗HIV一直是吉利德科学的业务核心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1750672598921205915","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["MAA","BK4585","BK4215","EMA","BK4081","BK4588"],"gpt_icon":0},{"id":"2545438934","title":"XRP牛市起點？監管勝利是否足以引爆300%漲幅？","url":"https://stock-news.laohu8.com/highlight/detail?id=2545438934","media":"cryptonews","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545438934?lang=zh_tw&edition=fundamental","pubTime":"2025-06-22 09:00","pubTimestamp":1750554000,"startTime":"0","endTime":"0","summary":"\nXRP目前稳固运行在2美元上方，目前交易价格约为2.13美元，自2024年11月反弹前低点以来，涨幅已超过300%。然而，市场正显现出整理迹象。在2.15美元阻力位附近出现了一个看跌吞没形态，同时还有下降趋势线，表明卖压正在增强。50周期指数移动平均线（EMA）同样位于2.15美元附近，进一步强化了该价位作为技术阻力的意义。 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cryptonews.com/cn/news/xrp-price-analysis-can-regulatory-wins-sustain-the-rally-beyond-300/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"cryptonews_cn_highlight","symbols":["BK4585","EMA","BK4550","BK4588","FDN","BK4081"],"gpt_icon":0},{"id":"2544014999","title":"百奧泰：烏司奴單抗注射液獲歐洲藥品管理局人用藥品委員會積極意見","url":"https://stock-news.laohu8.com/highlight/detail?id=2544014999","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544014999?lang=zh_tw&edition=fundamental","pubTime":"2025-06-20 16:05","pubTimestamp":1750406759,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰(688177.SH)公告，公司近日收到了欧洲药品管理局(简称“EMA”)的通知，Usymro®(BAT2206，乌司奴单抗注射液)获得EMA人用药品委员会(简称“CHMP”)积极意见。CHMP建议欧盟委员会(EC)批准Usymro®上市，用于治疗成人及儿童的：中重度斑块状银屑病(PsO)，活动性银屑病关节炎(PsA)，中重度活动性克罗恩病(CD)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506201609209787a9de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506201609209787a9de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EC","BK4116","BK4081","CD","BK4201","EMA"],"gpt_icon":0},{"id":"2544194287","title":"一年兩針！吉利德突破性長效HIV療法獲FDA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2544194287","media":"药渡","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544194287?lang=zh_tw&edition=fundamental","pubTime":"2025-06-20 07:31","pubTimestamp":1750375894,"startTime":"0","endTime":"0","summary":"4吉利德深耕HIV领域吉利德科学公司在HIV治疗和预防领域拥有超过35年的创新经验。吉利德致力于通过科学创新提供满足HIV患者不断变化需求的解决方案。通过与全球健康倡导者和组织的合作，吉利德还旨在改善教育、扩大药物可及性，并解决护理障碍，目标是终结全球HIV流行。这种每年仅需注射两次的长效方案有望显著提高患者的依从性，降低HIV传播风险，推动全球HIV预防目标的实现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620073702a7135975&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620073702a7135975&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EMA","LU1571399168.USD","LU1585245621.USD","MAA","LU2087621335.USD","IE00B7SZLL34.SGD","LU0234570918.USD","LU0058720904.USD","LU0889565916.HKD","IE00B19Z3B42.SGD","LU1430594728.SGD","GILD","IE00B19Z3581.USD","IE00BKVL7J92.USD","LU0289739699.SGD","IE00B3T34201.USD","LU1839511570.USD","BK4532","LU0320765992.SGD","BK4568","BK4550","IE00BSNM7G36.USD","LU1066051498.USD","LU1674673691.USD","IE00BZ1G4Q59.USD","BK4566","BK4583","LU1066053197.SGD","BK4139","BK4578","LU0823416689.USD","LU1778281490.HKD","BK4588","BK4585","LU2089984988.USD","LU0109394709.USD","LU1674673428.USD","IE0002270589.USD","LU2468319806.SGD","BK4081","BK4215"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"date":"2025-08-08","symbol":"EMA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":null,"defaultRemindTime":1754640000000,"name":null,"time":"盤前","dateTimestamp":1754625600000,"actualEps":null},{"date":"2025-08-01","symbol":"EMA","amount":0.725,"announcedDate":"2025-07-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-01","defaultRemindTime":1754055000000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-15","payableDate":"2025-08-01","currency":"CAD","dateTimestamp":1754020800000,"payDate":"2025-08-15"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2015-07-29","recordDate":"2015-07-31","paymentDate":"2015-08-17","value":0.305564,"currency":"USD"},{"executeDate":"2015-10-29","recordDate":"2015-11-02","paymentDate":"2015-11-16","value":0.3565682,"currency":"USD"},{"executeDate":"2016-01-29","recordDate":"2016-02-02","paymentDate":"2016-02-16","value":0.3421147,"currency":"USD"},{"executeDate":"2016-04-28","recordDate":"2016-05-02","paymentDate":"2016-05-16","value":0.3682105,"currency":"USD"},{"executeDate":"2016-07-20","recordDate":"2016-07-22","paymentDate":"2016-08-15","value":0.4045038,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.0667,"buy":0.4,"hold":0.4667,"sell":0,"strongSell":0.0667,"meanLabel":"HOLD","meanPercent":0.4667,"analysts":15,"updateTime":1750996800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2025-07-14","current":19.892644,"percent":1,"low":19.106036,"twenty":19.29558,"median":19.444056,"eighty":19.706259,"high":19.892644,"avg":19.484808,"sd":0.225957,"marketCap":13708838252.81},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-14","current":19.892644,"twenty":19.29558,"median":19.444056,"eighty":19.706259,"marketCap":13708838252.81}],"updateTime":1752636598899}}}